Washington, D.C. 20549









Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 1, 2021




Akero Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-38944   81-5266573

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


601 Gateway Boulevard, Suite 350

South San Francisco, CA

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (650) 487-6488


Not Applicable

(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share AKRO The Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07.  Submission of Matters to a Vote of Security Holders.


Akero Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 1, 2021. As of April 5, 2021, the record date for the Annual Meeting, there were 34,820,319 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April 27, 2021: (i) to elect three directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D., and Yuan Xu, Ph.D., as Class II directors of the Company to each serve for a three-year term expiring at the Company’s annual meeting of stockholders in 2024 and until their successors have been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (“Proposal 2”).


The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class II directors as follows:


Class II Director Nominee  For   Withheld   Broker Non-Votes 
Seth L. Harrison, M.D.   21,800,912    4,780,457    5,298,544 
Graham Walmsley, M.D., Ph.D.   21,775,483    4,805,886    5,298,544 
Yuan Xu, Ph.D.   26,548,435    32,934    5,298,544 


The Company’s stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. The votes cast at the Annual Meeting were as follows:


For   Against   Abstain 
 31,788,019    12,437    79,457 


No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.


*      *       *







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Andrew Cheng
    Andrew Cheng, M.D., Ph.D.
    President and Chief Executive Officer